Holds one active US DMF for daclatasvir, filing since 2016. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for daclatasvir, filing since 2018. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.
Holds 2 active US DMFs for daclatasvir, filing since 2018. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for daclatasvir, filing since 2018. Its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for daclatasvir. Its GMP is recognised in 1 market.
Registered with SFDA (Saudi Arabia) for daclatasvir.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Open the full list with a free accountContract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free